Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti ‐PLA2R positive primary membranous nephropathy

DiscussionWith proven efficacy in removing IgG antibodies and its use as a relatively safe treatment option in a multitude of conditions, immunoadsorption has the potential to offer patients with primary MN a more directed therapy free from the short and long‐term side‐effects generally seen in this condition.

Source: Journal of Clinical Apheresis - October 1, 2017 Category: Hematology Authors: Patrick Hamilton, Durga Kanigicherla, Prasanna Hanumapura, Lars Walz, Dieter Kramer, Moritz Fischer, Paul Brenchley, Sandip Mitra Tags: RESEARCH ARTICLE Source Type: research